PROCEPT BioRobotics (PRCT) Faces Fresh Class Action As Fair Value Debate Persists

PROCEPT BioRobotics (PRCT) is back in focus after a fresh class action filing that challenges its past sales practices, inventory levels, and financial disclosures. This development is putting legal risks and business transparency under closer investor scrutiny.

See our latest analysis for PROCEPT BioRobotics.

The latest legal filing lands after a tough stretch for PROCEPT BioRobotics shareholders. The stock closed at US$18.62, with a 7 day share price return of 11.56% that follows a 30 day share price return down 11.46% and a year to date share price return down 39.47%. The 1 year total shareholder return is down 62.73% and the 3 year total shareholder return is down 46.37%. Recent news now appears to be shaping market views on both growth prospects and legal risk.

If this class action has you reassessing your exposure to medical technology, it could be a good time to scan a wider field of surgical and automation peers with the 36 robotics and automation stocks

After a sharp reset in PROCEPT BioRobotics and fresh legal uncertainty around past sales, the stock now sits near US$18. The next step is to assess whether that risk profile still aligns with the current valuation.

Most Popular Narrative: 26.3% Undervalued

According to the most followed narrative on PROCEPT BioRobotics, a fair value of $25.26 is set against the last close at $18.62. That gap is helping frame the latest legal headlines as a potential valuation distortion rather than a shift in the long term story.

I have been an investor in PRCT since before IPO. The wild fluctuations in share price recently make no sense. The sell side analyst who chased the share price up to highs in 2024 (when the price was way too frothy) are doing the same thing now by revising the share price lower and lower, when clearly the company is still doing a great job. The recent downgrade by Leerink, citing PAE as a possible headwind for PRCT growth, is in direct opposition to what Larry Wood (CEO) stated at the last earnings call. To quote Larry Wood, “I don’t think PAE is a headwind for us at all. I think PAE is a big red herring. It’s a procedure that really does not get performed in any volume in Europe. And the reason it doesn’t get performed is because it doesn’t get paid for because it’s not a very good procedure.”

Read the complete narrative.

Want to understand why this narrative still sees upside for PROCEPT BioRobotics despite legal noise and recent share price weakness? The story leans heavily on sustained revenue expansion, improving margins and a future earnings multiple that assumes meaningful progress from today’s loss making base. Curious which specific growth and profitability assumptions sit behind that $25.26 fair value and how they contrast with recent market moves. The full narrative lays out those numbers in detail.

Result: Fair Value of $25.26 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this bullish PROCEPT BioRobotics narrative could be hit by further class action developments or any disappointment relative to the revenue and profitability assumptions behind it.

Find out about the key risks to this PROCEPT BioRobotics narrative.

Another View: PROCEPT BioRobotics Through The Sales Multiple Lens

The fair value narrative for PROCEPT BioRobotics leans on future growth and margin progress. The market today is instead anchoring on revenue, with the stock trading on a P/S of 3.3x. That is higher than the US Medical Equipment industry average of 2.9x, but lower than the peer average of 5.3x and close to the fair ratio of 3.4x that the market could move towards. For investors, this mix of slightly above industry, below peers and near the fair ratio raises a simple question. Is PROCEPT BioRobotics priced for enough execution risk around growth, profitability and the new legal overhang?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on PROCEPT BioRobotics clearly split between concern and cautious optimism, now is a good time to review the numbers yourself and move quickly. To weigh both sides of the story, including the risks investors are worried about and the potential rewards that still attract interest, start with the 1 key reward and 1 important warning sign

Looking for more investment ideas beyond PROCEPT BioRobotics?

If you stop at PROCEPT BioRobotics, you could miss other opportunities that fit your goals just as well. Use the Simply Wall St Screener to compare ideas efficiently.

• Spot potential mispricings by checking out companies highlighted in the 55 high quality undervalued stocks that may offer a more attractive balance between quality and price.
• Strengthen your focus on financial resilience by scanning the solid balance sheet and fundamentals stocks screener (45 results) for stocks that pair healthier balance sheets with fundamental support.
• Get ahead of the crowd by reviewing the screener containing 19 high quality undiscovered gems and see which underfollowed stocks stand out on quality metrics before wider attention arrives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com